摘要
目的探讨山楂果胶寡糖与氟喹诺酮联合用药对金黄色葡萄球菌防耐药浓度的影响,为临床合理使用现有抗生素、防治细菌耐药产生提供理论依据。方法采用标准琼脂二倍稀释法测定左氧氟沙星、环丙沙星对30株临床分离的金黄色葡萄球菌和金黄色葡萄球菌质控菌株ATCC25923的最低抑菌浓度(MIC),采用标准琼脂平板稀释法测定2种FQ药物对临床分离金黄色葡萄球菌的防突变浓度,计算单药和联合山楂果胶寡糖用药后该药的MPC50、MPC90。结果左氧氟沙星单药对30株金黄色葡萄球菌的MPC范同在2~64mg/L,MPC90为32mg/L;联合山楂果胶寡糖后MPC范围为0.5~16mg/L,MPC90降至8mg/L。环丙沙星单药对30株金黄色葡萄球菌的MPC范围1~32mg/L,MPC90为16mg/L;联合山楂果胶寡糖后MPC范围0.25~8mg/L,MPC90降至4mg/L,两组各项指标比较差异有显著性伊〈0.05)。结论联合山楂果胶寡糖用药能降低环丙沙星、左氧氟沙星MPC,减少细菌耐药突变体的选择性富集扩增,防止抗菌药物耐药的产生。
Objective To provide supporting evidence tor logical use of antibiotics by exploring the influence of combination therapy with Haw Pectin-derived pectic oligosaccharieds and fluoroquinolones on mutant prevention concentration of Staphylococcus aureus, Methods Minimal inhibitory concentrations (MIC) of levofloxacin and ciprofloxacin for staphylococcus aureus and quality control (ATCC25923) were determined by the standard two-fold agar dilution methods. MPC of fluoroquinolones for the strains were determined by spreading 10^10cfu/ml coccus on agar plates containing single or two drugs at different concentrations. The values of MPC50 and MPC90 were calculated. Results For 30 clinical isolated ciprofloxacin and oxacillin-susceptible Staphylococcus aureus, MPC of levofloxacin alone was 2-64 mg/L and MPC90 was 32 mg/L and they reduced to 0.5-16mg/L and 8 mg/L on levofloxacin combined with pectic oligosaccharieds; MPC of of ciprofloxacin alone was 1-32 mg/L and MPC90 was 16 mg/L and they declined to 0.25-8 mg/L and 4 mg/L on ciprofloxacin plus pectic oligosaccharieds. Conclusions Combination with Haw Pectin-derived pectic oligosaccharieds can decrease MPCs of levofioxacin and ciprofloxacin, reduce the proliferation of drug-resistant mutants, and prevent the occurrence of drug resistance.
出处
《国际医药卫生导报》
2010年第12期1459-1462,共4页
International Medicine and Health Guidance News
关键词
氟喹诺酮
联合用药
金黄色葡萄球菌
防突变浓度
Fluoroquinolone
Combination therapy
Staphylococcus aureus
Mutant prevention concentration